Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024

Fineline Cube Mar 8, 2024

Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...

Company Drug

China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833

Fineline Cube Mar 8, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem

Fineline Cube Mar 7, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...

Company Drug

Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China

Fineline Cube Mar 7, 2024

German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from...

Company Deals

Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio

Fineline Cube Mar 7, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million

Fineline Cube Mar 7, 2024

BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and...

Company Drug

Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau

Fineline Cube Mar 7, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch...

Company Deals

Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912

Fineline Cube Mar 7, 2024

Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a...

Legal / IP Policy / Regulatory

US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data

Fineline Cube Mar 7, 2024

The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...

Company Drug

CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point

Fineline Cube Mar 7, 2024

China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...

Company Drug

Xian Janssen’s Tremfya Heads for Priority Review in China for Crohn’s Disease Treatment

Fineline Cube Mar 7, 2024

The Center for Drug Evaluation (CDE) has indicated that Xian Janssen Pharmaceutical’s Tremfya (guselkumab), an...

Company Drug

EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma

Fineline Cube Mar 7, 2024

The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...

Company Drug

Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial

Fineline Cube Mar 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...

Company Deals

Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers

Fineline Cube Mar 7, 2024

Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....

Company Drug

Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals

Fineline Cube Mar 7, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company

Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters

Fineline Cube Mar 6, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...

Company Drug

Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer

Fineline Cube Mar 6, 2024

The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...

Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Posts pagination

1 … 387 388 389 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.